Program
Allogeneic Invariant Natural Killer T-cells agenT-797
Also written as “agenT-797” and “Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)”.
Its studies are mostly in Respiratory Distress Syndrome · Pneumonia · Neoplasms · Multiple Myeloma, led by 3 companies.
Drug pageAllogeneic Invariant Natural Killer T-cells agenT-797: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agenusits history only | 30 open or running | phase 1since Oct 6, 2020 | Oct 6, 2020 | none ahead |
| ImmunityBio | 10 open or running | phase 2since Mar 13, 2026 | Mar 13, 2026 | none ahead |
| MiNK Therapeuticsits history only | 11 open or running | phase 2since May 22, 2026 | May 22, 2026 | Jun 2027phase 2 · NCT07615010 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of ImmunityBio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 13, 2026First study: phase 2 study in Respiratory Distress SyndromeFirst studyNCT07492888
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study ImmunityBio leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07492888Respiratory Distress Syndrome | 2 | Withdrawn | Nov 15, 2026 | 0 |
How it is read
Names in the registry
- “agenT-797”, 4 entries
- “Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Distress Syndrome, 2 studies
- Pneumonia, 1 study
- Neoplasms, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.